Table 1.

Medline published studies that assess the effect of AZ in COVID-19

	Inpatient		Outpatient
	AZ alone	AZ+HQ	AZ alone	AZ+HQ
Studies favouring AZ	one retrospective study: Albani et al70	Five retrospective studies: Arshad et al72 Tanriverdi et al88 d’Arminio et al89 Sekhavati et al90 Lauriola et al91	one retrospective study: Guérin et al73	one retrospective study: Guérin et al73
Studies neutral to AZ	six retrospective studies: Kuderer et al71 Geleris et al92 Rosenberg et al75 Ip et al93 Rodriguez-Molinero et al94 Lammers et al95	five retrospective studies: Satlin et al96 Ip et al93 Magagnoli et al97 Ayerbe et al98 Young et al99	two retrospective studies: Kuderer et al71 Szente et al74
	1 RCT: Cavalcanti et al76	1 RCT: Furtado et al100
Studies not favouring AZ		2 Retrospective studies: Kuderer et al71 Rosenberg et al75		one retrospective study: Kuderer et al71
		1 RCT: Cavalcanti et al76

PubMed was searched with the search term (‘COVID-19’ or ‘SARS-CoV-2’) and ‘azithromycin’. A total of 537 titles and/or abstracts were screened. Studies that compared combination regimens and from which no individual treatment effect of azithromycin could be deduced were excluded.

AZ, azithromycin; HQ, hydroxychloroquine; RCT, randomised controlled trial.